1Bulk S, Berkhof J, Bulkmans NW, et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV 18 for adenoeareinoma of the cervix compared to women with normal cytology in the netherlans [J]. Br J Cancer,2006,94(1) :171-175.
2Kiatpongsan S, Niruthisard S, Mutirangura A, et al. Role of human papillomavirus DNA testing in management of women with atypical squamous cells of undetermined sigmificance[J]. Int J Gynecol Cancer,2006,16(1), 262-265.
3Lie AK,Risberg B, Borge B, et al. DNA versus RNA based methods for human papillomavirus detection in cervical neoplasia [J]. Gynecol Oncol, 2005,9(3):908-915.
4Urquiza M,Guevara T,Espejo F,et al. Two L1-peptides are excellent tool for serological detection of HPV-associated cervical carcinoma le sions[J]. Biochem Biophys Res Commun, 2005,332 (1) : 224- 232.
5Molano M,Vanden-Brule A,Plummer M,et al. Determinant of clearance of human papillomavirus infection in colombian women with norreal cytology: A populatiorrbased, 5 year follow up study[J]. Am J Epidemiol, 2003,158 (5) : 486-494.
6Cricca M, Venturoli S, Morselli-Labate A, et al. HPV DNA patterns and disease implications in the follow-up of patients treated for HPV16 high-grade carcinoma in situ[J]. J Med Virol, 2006,78(4): 495-500.
7Song SH,Lee JK,Oh MJ,et al. Persistent HPV infection after conixation in patients with negative margins[J]. Gynecol Oncol, 2006,101 (3) :418-422.
8Sikorski M, Bieda T,Bobek M,et al. Dynamics of cervical langerhans cell counts in the course of HPV-positive CIN treatment with the use of human recombinant interferon gamma[J]. Eur J Gynaecol Oncot, 2005,26(3) :294-298.
9Villa LL,Costa RL,Petta CA,et al. Prophylactic quadrivalent human papillornavirus (types6,11,16 and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multi centre phase Ⅱ efficacy trial[J]. Lancet Oncol,2005,6(5) :256-257.
10Garcia-hernandez E, Gonzalez-Sanchez JL, Andrade-Manzano A, et al. Regression of papilloma higt-grade lesions (CIN2 and CIN3 ) is stimulated by therapeutic vaccination with MVA E2 recombinant vac dne[J]. Cancer Gene Ther,2006,13 (6) : 592-597.
7DellG,Gaston K.Human papillo maviruses and their role in cervical cancer[J].Cell Mol Life SCi,2001,58 (12～13):1923-1942.
8Munoz N,Bosch FX,de Sanjosé,et al.Epidemiologic classificationofhuman papillomavirus types associated with cervical cancer[J].The NEW ENGLAND JOURNAL of MEDICINE,2003,348 (6):518-527.
9Clifford GM,Smith JS,PlummerM et al.Human papillomavirus typesin invasive cervical cancer worldwide:a meta-analysis[J].Br J Cancer,2003,88 (1):63-73.
10CoglianoV,BaanR,StraifK etal.Carcinogenicity of human papilloma-viruses[J].Lancet Oncol,2005,6 (4):204.
